{"doi":"10.3389/fimmu.2025.1675554","title":"Case Report: Telitacicept in the treatment of cSLE-APS: novel therapeutic perspectives on autoimmune thrombotic diseases in children","abstract":"<jats:p>Thrombotic antiphospholipid syndrome (APS) in Childhood-onset systemic lupus erythematosus (cSLE) remains a therapeutic frontier. Here, we report the first case of telitacicept (a TACI-Fc fusion protein)- induced remission in cSLE related antiphospholipid syndrome (cSLE-APS), where targeted dual BAFF(B cell-activating factor)/APRIL(a proliferation-inducing ligand) inhibition resolved life-threatening infarctions and achieved sustained disease control. During treatment, corticosteroids were successfully discontinued within six months, and a lupus low disease activity state (LLDAS) was maintained. Our findings indicate that telitacicept’s unique ability to regulate B-cell activity could target the dual pathology of cSLE-APS, offering a new therapeutic approach for this serious condition.</jats:p>","journal":"Frontiers in Immunology","year":2026,"id":623332,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1610873,"name":"Zhilang Cao","orcid":null,"position":1,"is_corresponding":false},{"id":159560,"name":"Yajun Wang","orcid":"0000-0003-1445-3943","position":2,"is_corresponding":false},{"id":488868,"name":"Jing Zheng","orcid":"0000-0002-2224-2372","position":3,"is_corresponding":false},{"id":88569,"name":"Jingyue Liu","orcid":"0000-0002-2267-1433","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Case Report: Telitacicept in the treatment of cSLE-APS: novel therapeutic perspectives on autoimmune thrombotic diseases in children","abstract":"<jats:p>Thrombotic antiphospholipid syndrome (APS) in Childhood-onset systemic lupus erythematosus (cSLE) remains a therapeutic frontier. Here, we report the first case of telitacicept (a TACI-Fc fusion protein)- induced remission in cSLE related antiphospholipid syndrome (cSLE-APS), where targeted dual BAFF(B cell-activating factor)/APRIL(a proliferation-inducing ligand) inhibition resolved life-threatening infarctions and achieved sustained disease control. During treatment, corticosteroids were successfully discontinued within six months, and a lupus low disease activity state (LLDAS) was maintained. Our findings indicate that telitacicept’s unique ability to regulate B-cell activity could target the dual pathology of cSLE-APS, offering a new therapeutic approach for this serious condition.</jats:p>","is_dataset_classified":null,"base_score":0.0,"endowment":0.0,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"41726182","pmcid":"PMC12920562","openalex_id":"https://openalex.org/W7127946206","authors":[],"funders":[],"total_grants":0,"fwci":0.0,"citation_percentile":0.11441374,"influential_citations":0,"citation_trend":[],"oa_status":"gold","license":"cc-by","oa_locations":[{"url":"https://public-pages-files-2025.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1675554/pdf","host_type":"journal"},{"url":"https://public-pages-files-2025.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1675554/pdf","host_type":"publisher"},{"url":"https://www.frontiersin.org/articles/10.3389/fimmu.2025.1675554/full","host_type":"publisher"},{"url":"https://doi.org/10.3389/fimmu.2025.1675554","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/41726182","host_type":"repository"},{"url":"https://doaj.org/article/fd628b8305df47ec851ad0e68e603351","host_type":"repository"},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12920562/","host_type":"repository"},{"url":"https://europepmc.org/articles/PMC12920562","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC12920562?pdf=render","host_type":"Europe_PMC"}],"fields_of_study":["Systemic Lupus Erythematosus Research","Diabetes and associated disorders","Otitis Media and Relapsing Polychondritis"],"mesh_terms":["B-Lymphocytes","Child","Female","Humans","Lupus Erythematosus, Systemic","Male","Recombinant Fusion Proteins","Thrombosis","Antiphospholipid Syndrome","Treatment Outcome","B-Cell Activating Factor","Tumor Necrosis Factor Ligand Superfamily Member 13"],"keywords":["Antiphospholipid syndrome","Therapeutic approach","Disease","Systemic lupus erythematosus","Autoimmune disease","Thrombosis","B-cell","Childhood-onset Systemic Lupus Erythematosus","Thrombotic Event","Telitacicept"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-03T23:19:04.094289Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}